scholarly journals The Differentiation of Firm Survival Models in the Poviats of the Zachodniopomorskie Voivodeship

2017 ◽  
Vol 4 (330) ◽  
Author(s):  
Iwona Markowicz
Keyword(s):  
Survival Function ◽  
Stage Iv ◽  
Firm Survival ◽  
Intensity Function ◽  
Stage Iii ◽  
Survival Models ◽  
Survival Duration ◽  
Kaplan Meier ◽  
Study Results

The aim of the study was to construct models of firms’ survival duration for individual poviats in the Zachodniopomorskie Voivodeship. The first stage was the calculation of the Kaplan‑Meier estimator and the use of a test for the verification of similarities in the survival function for the analysed poviats. As a result, groups of poviats were created. The next stage of research was the construction of duration tables of the studied firms and an analysis of the intensity function of firms’ liquidation for the poviats. The percentage of firms liquidated after two years of activity in different poviats (stage III) was presented. An analysis of correlation between the percentage of firms liquidated in the analysed period and the number of entities registered per 10 thousand of population in the poviats (stage IV) was also conducted. This study used data from the registry of REGON related to companies established in the Zachodniopomorskie Voivodeship in 2009–2011. These entities were observed till the end of 2013. The study results reveal the differentiation of firm survival models in the poviats of the Zachodniopomorskie Voivodeship. Five groups of poviats were distinguished and characterised.

Contemporary utilization trends of systemic chemotherapy for upper tract urothelial carcinoma (UTUC).

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 441-441
Author(s):  
Mohammed Haseebuddin ◽  
Elizabeth Handorf ◽  
Joshua Jones ◽  
Alexander Kutikov ◽  
Nikhil Waingankar ◽  
...  
Keyword(s):  
Temporal Trends ◽  
Logistic Models ◽  
Stage Iv ◽  
Stage Ii ◽  
Stage Iii ◽  
Rank Tests ◽  
Chi Square ◽  
Clinicopathologic Characteristics ◽  
Kaplan Meier ◽  
To Receive

441 Background: There is currently no consensus regarding the use of systemic therapy (ST) for surgically-treated patients with invasive UTUC. Using a large national cancer registry, our objective was to assess temporal trends in utilization of ST for stage II-IV UTUC undergoing definitive resection. Methods: The National Cancer Database (NCDB) was queried for all patients surgically treated (nephroureterectomy, segmental resection) for stage II-IV UTUC from 1998-2012. Temporal trends in receipt of ST [neoadjuvant (NAT), adjuvant (AT), or unknown timing (UKT)] were assessed using chi square analyses. After exclusion of patients receiving NAT or UKT, adjusting for patient and clinicopathologic characteristics, multivariable logistic models were used to examine the association between clinicopathologic characteristics and receipt of ST within 9 months of resection. Kaplan Meier analyses and stratified log-rank tests were performed comparing overall survival (OS) between patients receiving ST < 9 months and those who did not. Results: Of 7,629 patients identified over the study period, 24.1% of patients surgically treated for stage II-IV UTUC received any ST (NAT: 1.44%, AT: 19.11%, UKT: 3.51%). Utilization of any ST significantly increased from 1998-2012 (20.2% vs. 28.7%, p < 0.0001). Following adjustment, patients of increased age (61-70 years: OR 0.62 [CI 0.42-0.91], 71+ years: OR 0.26 [CI 0.17-0.38]) were less likely to receive ST, and patients with high grade (OR 2.46 [CI 1.95-3.09]), Stage III (OR 4.75 [CI 3.89-5.79]), and Stage IV (OR 9.37 [CI 7.49-11.74]) disease were more likely to be treated with ST. When restricted to stage III-IV disease, receipt of ST < 9 months was significantly associated with improved OS after adjustment for age, grade, and charlson index (p < 0.002). Conclusions: In hospitals reporting to the NCDB, while utilization has significantly increased from 1998-2012, less than one third of patients surgically treated for stage II-IV UTUC receive ST. In addition to unmeasured characteristics (decline of renal function following surgery), the lack of explicit guidelines and prospective evidence may contribute to limited use of systemic treatment.

Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- β2 inhibitor AP 12009

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4607-4607 ◽  
Author(s):  
H. Oettle ◽  
T. Seufferlein ◽  
R. Schmid ◽  
T. Luger ◽  
S. Ludwig ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Phase I ◽  
Pancreatic Carcinoma ◽  
Dose Escalation ◽  
Dose Group ◽  
Stage Iv ◽  
Stage Iii ◽  
Dose Escalation Study ◽  
Study Results ◽  
Grade 3

4607 Background: TGF-β2 plays a pivotal role in tumor progression as it regulates key mechanisms, namely immunosuppression, metastasis, angiogenesis, and proliferation. The TGF-β2 inhibitor AP 12009 has shown clinical efficacy including complete and long-lasting remissions in patients with high-grade glioma. Methods: The currently ongoing clinical phase I/II study AP 12009-P001 is an open-label, multicenter, dose-escalation study. AP 12009 is being administered intravenously in adult patients with pancreatic carcinoma (PC, stage IVA/IVB), metastatic melanoma (MM, stage III/IV), or advanced colorectal carcinoma (CRC, stage III/IV). Primary endpoint is determination of the maximum tolerated dose (MTD). 3 to 6 patients per cohort (dose group) were enrolled into this dose escalation study. Results: So far, 17 patients have been treated in four dose groups, 11 patients with PC, 2 with MM, and 4 with CRC. Per cycle, AP 12009 was applied as a continuous i.v. infusion at weekly intervals in an out-patient setting. The 17 patients received one to ten cycles of AP 12009 (mean: 2.8). At the current stage, no (possibly) drug related serious adverse event (SAE), and only 17 (possibly) drug related adverse events (AEs) in eight patients have been observed. The 17 patients received one to ten cycles of AP 12009. Three dose-limiting toxicities (DLTs) occurred in the 4th dose group (exanthema grade 3 in one patient, thrombocytopenia grade 3 in two patients) and consequently, the MTD was determined as being 160 mg/m2/day with the current administration schedule. One patient suffering from MM stage IV is still alive 64 weeks after start of treatment. Moreover, one PC patient (stage IV) from the 2nd cohort is still after 72 weeks, having experienced a complete response. Further dose escalation studies in PC, MM, and CRC patients using a modified schedule are currently in preparation. Conclusions: In conclusion, encouraging case reports from the phase I/II study along with a good safety profile form a rational basis for the use of the TGF-β2 inhibitor AP 12009 as targeted therapy for advanced solid tumors such as PC, MM and CRC. No significant financial relationships to disclose.

scholarly journals ANGKA BANDING NEUTROFIL/LIMFOSIT DI KARSINOMA PAYUDARA

2018 ◽  
Vol 21 (2) ◽  
pp. 125
Author(s):  
Yuly Eko Prasetyo ◽  
Uleng Bahrun ◽  
Ruland DN. Pakasi
Keyword(s):  
Early Stage ◽  
Stage Iv ◽  
Abdominal Ultrasound ◽  
Prognostic Indicator ◽  
Stage Iii ◽  
Neutrophil Lymphocyte Ratio ◽  
Post Hoc Analysis ◽  
Study Results ◽  
The Mean ◽  
Post Hoc

Carcinoma Mammae (CM) is a malignancy of epithelial cells restricting at the breast ducts or lobes which causes very high mortalityrate. The Neutrophil/Lymphocyte ratio (NLR) is reflecting the inflamatory status, has been reported to be a prognostic indicator in somemalignant tumors. The purpose of this study is to know the NLR as an indicator of the progressivity of CM by analyzing it. A retrospectiveobservational study performed using data from the medical record of CM patients at Wahidin Sudirohusodo Hospital from January 2010up to December 2012. The diagnosis were established by the clinicians based on the result of histopathological exsamination, chest X-ray,abdominal ultrasound, bone scan and CT scan. The patients with surgical history, chemotherapy, radiotherapy, leukocytes >12.000/mm3and incomplete data were excluded from the analysis. The data distribution was analyzed using Kolmogorov-Smirnov test. The relationbetween NLR in CM was analized by One way ANOVA test and post hoc analysis. The result were 130 samples, consisting of 17 patientsin early stage, 71 in stage III and 42 in stage IV CM. In the early stage the mean of NLR were 1.69, 2.04 in stage III and 2.89 in stage IVand their differences were statistically significant (p<0.001). Post hoc analysis showed that the significant differences occurred betweenthe early stage and IV, as well as between stage III and IV. The mean of NLR were 2.28±1.02 in the non metastatic and 3.36±1.5 in themetastatic they were statistically significant (p<0.001). Based on the study results can be concluded that the neutrophil/lymphocyteratio can be used to assess the progressivity of CM. Further studies with larger samples were needed for the determination of the cut offpoint of NLR.

Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3500-3500 ◽  
Author(s):  
Thierry Andre ◽  
Franck Bonnetain ◽  
Laurent Mineur ◽  
Jaafar Bennouna ◽  
Jérôme Desrame ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Free Survival ◽  
Stage Iii Colon Cancer ◽  
Longitudinal Measurements ◽  
Kaplan Meier ◽  
Study Results

3500 Background: The IDEA international collaboration was established to combine data from 6 randomized trials to assess whether a 3-month (3M) of oxaliplatin/fluoropyrimidines-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) for 3-year disease free survival (DFS) in stage III colon cancer (CC). Methods: French IDEA randomized patients (pts) between 3M and 6M of CT with mFOLFOX6 or XELOX (physician/pts choice). DFS was estimated using the Kaplan–Meier method and described using 3 years DFS rate. Results: Among 2022 randomized pts between May 2009 and May 2014, 2010 (99.4%) received CT and were enrolled in the mITT population: 49.9 and 50.1% in 3M and 6M, respectively. 99.5% of the mITT pts had stage III (N1: 74.9%; N2: 25.2%); median age 63.9 years; mFOLFOX6: 90% and XELOX 10% of pts. DFS median follow-up is 50.2 months. There were 578 DFS events (314 in 3M and 264 in 6M arm) leading to a 3-year DFS rate of 72.1% in the 3M vs. 75.7% in the 6M (HR=1.24; 95%CI 1.05–1.46, p=0.0112). For pts receiving mFOLFOX6, 3-year DFS rate was 72.0% in the 3M vs. 76.3% in the 6M (HR=1.27; 95%CI 1.07–1.51 p=0.0069). 94.2% and 78.0% of pts completed 3 and 6 months of CT, respectively. Median oxaliplatin doses intensity were 96.9% in 3M and 72.1% in 6M (495.0 and 735.1 mg/m2). By considering the neuropathy grade with 15375 neuropathy longitudinal measurements the overall maximal neuropathy grade 0-1/2/3-4 was 63.6/28.5/7.9% in 3M and 33.4/41.3/25.3% in 6M; p<0.0001. At last follow-up assessment, with a median of 43.1 months, final residual grade 2/3-4 neuropathy was 2.1/0.4% in 3M and 5.4/1.3% in 6M; p<0.0001. Conclusions: The IDEA France study, with 90% of patients treated with mFOLFOX6 regimen has shown that 6 months adjuvant treatment is superior to 3 months treatment. IDEA France study results should be considered in line with the international IDEA project that will also be presented at ASCO 2017. Clinical trial information: 2009-010384-16.

Assessment of Deterioration of Highway Pavement using Bayesian Survival Model

2020 ◽  
Vol 2674 (6) ◽  
pp. 310-325
Author(s):  
Sylvester Inkoom ◽  
John O. Sobanjo ◽  
Eric Chicken ◽  
Debajyoti Sinha ◽  
Xufeng Niu
Keyword(s):  
Failure Time ◽  
Survival Function ◽  
Survival Model ◽  
Survival Models ◽  
Survival Times ◽  
Underlying Distribution ◽  
Kaplan Meier ◽  
Bayesian Survival Model ◽  
Parametric Survival ◽  
Highway Pavement

The size and level of complexity of highway pavement data and its associated covariates have led to the application of different approaches in the analysis of the highway pavement data for deterioration modeling. With the goal of predicting the survival of highway pavement with interpretable and reproducible models that are robust to uncertainties, errors, and overfitting, the Bayesian survival model (BSM) is proposed in this paper as a good method of estimating parameters for survival functions. Deterioration patterns in relation to the failure time distribution are treated as random quantities sampled from some stochastic prior processes. The specified priors are combined with the data sampled to obtain the distribution of the survival function using Bayes theorem and the Markov chain Monte Carlo method. A posteriori distribution of the survival function is obtained from the pavement information and compared with the classical product limit survival (Kaplan-Meier) estimate and the univariate parametric survival function. This paper reports experimental results of the three candidate models and their efficiency in describing the survival of highway pavement in the presence of deterioration. It is observed from the BSM outcomes that the posterior estimates are accurate in estimating the survival times of roadway segments at 95% credible interval. The outputs also show the robustness of the BSM in describing the uncertainties associated with the survival of highway pavement compared with the Kaplan-Meier and the univariate parametric survival models in the event of limited data and misspecification of underlying distribution.

scholarly journals ADAR expression and copy number variation in patients with advanced gastric cancer

2020 ◽  
Author(s):  
Javad Behroozi ◽  
Shirin Shahbazi ◽  
Mohammad Reza Bakhtiarizadeh ◽  
Habibollah Mahmoodzadeh
Keyword(s):  
Gastric Cancer ◽  
Copy Number Variation ◽  
Copy Number ◽  
Stage Iv ◽  
World Health ◽  
Stage Iii ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Number Variation ◽  
Adar Gene

Abstract Background Gastric cancer (GC) is a world health problem and it is the third leading cause of cancer deaths worldwide. The current practice for prognosis assessment in GC is based on radiological and pathological criteria and they may not result in an accurate prognosis. The aim of this study is to evaluate expression and copy number variation of the ADAR gene in advanced GC and clarify its correlation with survival and histopathological characteristics. Methods Forty two patients with stage III and IV GC were included in this study. ADAR gene expression and copy number variation were measured by real-time PCR and Quantitative multiplex fluorescent-PCR, respectively. Survival analysis performed based on the Kaplan–Meier method and Mantel–Cox test. Results ADAR mRNA was significantly overexpressed in the tumor tissues when compared to the adjacent normal tissues (p <0.01). Also, ADAR expression level in stage IV was higher than stage III. 40% of patients showed amplification in ADAR gene and there was a positive correlation between ADAR copy number and expression. Increased ADAR expression was clearly correlated with poorer survival outcomes and Mantel–Cox test showed statistically significant differences between low and high expression groups (p <0.0001). ADAR overexpression and amplification were significantly associated with metastasis, size and stage of tumor. Conclusions Together, our data indicate that amplification leads to over expression of ADAR and it could be used as a prognostic biomarker for disease progression, especially for the metastatic process in GC.

Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6037-6037
Author(s):  
C. P. Rodriguez ◽  
D. J. Adelstein ◽  
J. P. Saxton ◽  
L. A. Rybicki ◽  
R. R. Lorenz ◽  
...  
Keyword(s):  
Performance Status ◽  
Cell Cancer ◽  
Cleveland Clinic ◽  
Stage Iv ◽  
Distant Metastases ◽  
Concurrent Chemotherapy ◽  
Stage Iii ◽  
Historical Cohort ◽  
Group V ◽  
Kaplan Meier

6037 Background: In patients (pts) with stage III-IV HNSCC, MACCRT has led to excellent locoregional control. Distant metastases (DM) are now the most common cause of treatment failure. This phase II study tested whether the oral EGFR inhibitor gefitinib (G) added to our Cleveland Clinic MACCRT regimen would decrease DM and improve survival. Methods: Between 4/03 and 9/07, 60 previously untreated pts with stage III-IV (M0) HNSCC, and a performance status of <1 were enrolled on this study. Pts received hyperfractionated radiation (72–74.4 Gy at 120cGy bid) and concurrent chemotherapy with cisplatin (20 mg/m2/day) and fluorouracil (1,000 mg/m2/day), both given as 96-hour continuous IV infusions during weeks 1 and 4. G 250 mg daily was begun on day 1 of the radiation and continued for 2 years. The results were retrospectively compared to our previous study of 44 pts treated with the same MACCRT regimen without G between 1/96 and 9/00. Results: The study population included a preponderance of Caucasian (97%) males (88%) with stage IV (80%) oropharynx tumors (68%), and with a median age of 58 (range 24–75) years. Patient and tumor characteristics were similar to the non-G treated historical cohort. When comparing the G vs. non-G treated pts, acute toxicities including transient renal dysfunction (28% v. 5% p = 0.002) and all-cause re-hospitalization (83% v. 64%, p = 0.022) were worse. Myelosuppression was similar. G-specific toxicity included > grade 1 rash in 60% and diarrhea in 35%. There were 5 deaths during treatment in the G group v. one in the non-G group (p = 0.19). Only a projected 44% of pts will complete the 2-year course of G. With a median follow-up in this trial of 37 (range 13–64) months, 3-year Kaplan-Meier outcome estimates do not differ between the study and the historical cohorts. Local control without surgery is 80% v. 88% (p = 0.21), DM control is 86% v. 76% (p = 0.19), freedom from recurrence is 72% v. 71% (p = 0.79), and overall survival is 67% v. 68% (p = 0.63) respectively. Conclusions: The addition of G to our MACCRT regimen was difficult for pts to complete. It did not improve any measured outcome and was associated with increased toxicity when compared to historical controls. [Table: see text]

A prospective evaluation of vascular endothelial growth factor (VEGF) and the immune system in stage III/IV melanoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20046-e20046
Author(s):  
Nicole Marie Agostino ◽  
Michael Weiss ◽  
Wenjing Shi ◽  
Wendy Kay Nevala ◽  
Stephen Hemperly ◽  
...  
Keyword(s):  
Immune System ◽  
Median Survival ◽  
Negative Correlation ◽  
Survival Curve ◽  
Stage Iv ◽  
Initial Therapy ◽  
Stage Iii ◽  
Positive Correlation ◽  
Gm Csf ◽  
Kaplan Meier

e20046 Background: The immune system and VEGF may play a role in melanoma behavior. We prospectively collected data in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes. Methods: We assessed median survival (MS), LDH, BRAF, VEGF, Th1/Th2 ratio, regulatory T cells (Tregs) and CD4/CD8 ratio, which were measured upon enrollment. LDH and BRAF were measured in standard commercial labs; VEGF via ELISA at LVHN; Th1/Th2 ratio and CD4/CD8 ratio via flow cytometry at Mayo Clinic. Stage III patients were treated with resection and interferon or observation. Stage IV patients were treated with some or all of the following: resection +/- GM-CSF, IL-2, ipilimumab, vemurafenib, carboplatin/paclitaxel/bevacizumab and temazolamide. Results: MS for stage IV patients was 48 months using a Kaplan-Meier survival curve. The only variable associated with survival was LDH, (HR=1.0017, 95%CI: 1.0003-1.0032, p=0.02). In stage IV patients, there was a positive correlation between VEGF and Tregs (r=.485, n=22 p=0.022) and a negative correlation between Tregs and Th1/Th2 (r=-.470, n=22, p=0.027). In stage III/IV patients who were alive at study completion, there was a positive correlation between CD4/CD8 and VEGF (r=.792, n=10, p=0.006). In patients who died, there was a negative correlation between Tregs and Th1/Th2 (r=-.660, n=12, p=0.02). 7 of the stage IV patients are currently disease free, including 5 of the 10 who received IL-2 +/- metastectomy. Conclusions: While a median survival of 48 months was provocative for stage IV patients, it may reflect referral selection at an IL-2 center. Recent advances such as ipilimumab (which lowers Tregs), BRAF inhibitors, and immunotherapy/aggressive resection as initial therapy may have impacted survival. The literature suggests that an elevated CD4/CD8 ratio predicts better outcomes. Higher VEGF levels have also been associated with lower overall survival in patients treated with IL-2. We found an association between higher VEGF levels and increased Tregs in deceased patients but not in living patients. In patients still alive, higher VEGF was balanced by a higher CD4/CD8 ratio. We did not find a correlation between baseline VEGF and survival.

Impact of digital multi-sided platforms on firm survival in retail

2021 ◽  
pp. 93-122
Author(s):  
E. S. Andronova ◽  
A. I. Rey ◽  
G. R. Akzhigitova
Keyword(s):  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Positive Impact ◽  
Survival Function ◽  
Firm Survival ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Data Set ◽  
Hazards Model ◽  
Kaplan Meier

This paper explores firm survival in Russian retail industry in cases of digital multi-sided platforms penetration such as aggregator Yandex.Market, marketplace Wildberries, electronic store Ozon and classified-ad service Avito. The panel data set of 130 thousand firms was analyzed using two methods: non-parametric Kaplan—Meier estimator and semi-parametric Cox proportional hazards model with time dependent covariates. Kaplan—Meier estimator calculates the survival function for censored data. Cox proportional hazards model examines the effect of platform penetration on hazard rates of differently sized firms in various industry spheres. Platforms-aggregators Yandex.Market and Wildberries have a strong positive impact on firm survival while platformsdisruptors Ozon and Avito increase likelihood of firm failure. The main results of platform influence in various industry spheres are as follows: the aggregator of price offers has a more positive impact on segments with high information asymmetry; and firms specialized on Wildberries key product categories enjoy lower hazard ratios of bankruptcy or liquidation. These hypotheses are not supported for Ozon and Avito platforms.

scholarly journals The halo model as a versatile tool to predict intrinsic alignments

2020 ◽  
Author(s):  
Maria Cristina Fortuna ◽  
Henk Hoekstra ◽  
Benjamin Joachimi ◽  
Harry Johnston ◽  
Nora Elisa Chisari ◽  
...  
Keyword(s):  
Degrees Of Freedom ◽  
Power Spectra ◽  
Stage Iv ◽  
Stage Iii ◽  
Radial Dependence ◽  
Additional Parameter ◽  
Small Scales ◽  
Cosmic Shear ◽  
Galaxy Populations ◽  
The Impact

Abstract Intrinsic alignments (IAs) of galaxies are an important contaminant for cosmic shear studies, but the modelling is complicated by the dependence of the signal on the source galaxy sample. In this paper, we use the halo model formalism to capture this diversity and examine its implications for Stage-III and Stage-IV cosmic shear surveys. We account for the different IA signatures at large and small scales, as well for the different contributions from central/satellite and red/blue galaxies, and we use realistic mocks to account for the characteristics of the galaxy populations as a function of redshift. We inform our model using the most recent observational findings: we include a luminosity dependence at both large and small scales and a radial dependence of the signal within the halo. We predict the impact of the total IA signal on the lensing angular power spectra, including the current uncertainties from the IA best-fits to illustrate the range of possible impact on the lensing signal: the lack of constraints for fainter galaxies is the main source of uncertainty for our predictions of the IA signal. We investigate how well effective models with limited degrees of freedom can account for the complexity of the IA signal. Although these lead to negligible biases for Stage-III surveys, we find that, for Stage-IV surveys, it is essential to at least include an additional parameter to capture the redshift dependence.

Sign in / Sign up

Export Citation Format

Share Document